DURECT Corp DC8A-FF:Frankfurt Stock Exchange

RT Quote | Exchange | EUR
Last | 9:10 AM CET
5.55quote price arrow down-0.05 (-0.89%)
52 week range
3.18 - 7.95
Loading...
  • Open5.55
  • Day High5.55
  • Day Low5.55
  • Prev Close5.37
  • 52 Week High7.95
  • 52 Week High Date01/18/23
  • 52 Week Low3.18
  • 52 Week Low Date01/02/23

Key Stats

  • Market Cap149.66M
  • Shares Out22.78M
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change79.15

KEY STATS

  • Open5.55
  • Day High5.55
  • Day Low5.55
  • Prev Close5.37
  • 52 Week High7.95
  • 52 Week High Date01/18/23
  • 52 Week Low3.18
  • 52 Week Low Date01/02/23
  • Market Cap149.66M
  • Shares Out22.78M
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change79.15

RATIOS/PROFITABILITY

  • EPS (TTM)-1.43
  • P/E (TTM)-3.88
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On DURECT Corp

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
DURECT Corporation is a biopharmaceutical company that is focused on advancing lifesaving investigational therapies. The Company's product candidates include DUR-928 oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. The Company’s other commercial product candidates include POSIMIR, PERSERIS and Methydur Sustained Release Capsules. The Company is conducting a Phase IIb study (AHFIRM) of larsucosterol (DUR-928) in subjects with severe...
David Hoffmann
Independent Chairman of the Board
James Brown
President, Chief Executive Officer, Director
Timothy Papp
Chief Financial Officer
Jian Li
Interim Principal Accounting Officer
Address
10260 Bubb Rd
Cupertino, CA
95014
United States